Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008

Haemophilia

Volumn 18, Issue 2, 2012, Pages 268-275

  Guh, S ^a   Grosse, S D ^a   McAlister, S ^a   Kessler, C M ^b   Soucie, J M ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Claims data; Cost of care; Employer sponsored insurance; Haemophilia; Inhibitor; MarketScan Commercial and Medicare databases

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR CONCENTRATE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ARTICLE; CASE FINDING; CHILD; CONTROLLED STUDY; COST OF ILLNESS; HEALTH CARE COST; HEALTH INSURANCE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH EXPENDITURES; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFANT; MALE; MIDDLE AGED; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 84857111181     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02692.x     Document Type: Article

References (14)

1. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
2. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
3. Soucie JM, Evatt B, Jackson D, and the Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998; 59: 288-94.
4. Aledort LM, Haschmeyer RH, Pettersson HA. Longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
5. Naraine VS, Risebrough NA, Oh P et al. Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique. Haemophilia 2002; 8: 112-20.
6. tEscobar MA. Health economics in haemophilia: a review from the clinician's perspective. Haemophilia 2010; 16(Suppl.3): 29-34.
7. Globe DR, Curtis RG, Koerper MA, the HUGS steering committee. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10(Suppl. 1): 63-70.
8. Tencer T, Friedman HS, Li-McLeod J, Johnson K. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. J Manage Care Pharm 2007; 13: 790-8.
9. Auerswald G, Von Depka Prondzinski M, Ehlken B et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004; 10: 499-508.
10. Bohn RL, Aledort LM, Putnam KG et al. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004; 10: 63-8.
11. Chang H, Sher GD, Blanchette VS et al. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 1999; 5: 247-52.
12. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high responding factor VIII and IX inhibitors. Haemophilia 2006; 12(Suppl. 6): 74-80.
13. Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
14. Soucie JM, Richardson LC, Evatt B et al. Risk factors for infection with hepatitis B and hepatitis C viruses in a large cohort of hemophilic males. Transfusion 2001; 41: 338-43.